Agenda and Schedule

This Town Hall will engage senior government officials with thought-leaders from industry, venture capital, academia, and the venture philanthropy and nonprofit sectors to explore new policy avenues to accelerate innovation.

7:45 a.m. – 8:15 a.m.
Meet & Greet (Coffee)

 

8:15 a.m.
Welcome: Chancellor Bernadette Gray-Little

                               

8:20 a.m. – 9:30 a.m.
Panel 1:  New Thinking
Christopher Austin, M.D. (Director, NIH Chemical Genomics Center) Roy Jensen, M.D. (Director, University of Kansas Cancer Center)
Barbara Kunz (President, Health and Life Sciences Global Business, Battelle)
Lesa Mitchell (Vice President, Kauffman Foundation)
Garry Neil, M.D. (Corporate Vice President, Corporate Office of Science and Technology, Johnson & Johnson)
Moderator: Lisa Richwine ( National Health Correspondent, Thomson-Reuters)

 

9:30 a.m.
Introduction of Sec. Sebelius: Chancellor Bernadette Gray-Little 

                                                                                 

9:30-10 a.m.
Key Note Address: Secretary Kathleen Sebelius

A policy platform to support and advance the role of academia in drug development 

                                                          

10:15 a.m. – 11:30 a.m.
Panel 2: New Competencies
Anthony J. Atala, M.D. (Director, Institute for Regenerative Medicine, Wake Forest University Baptist Medical Center)
James Baxendale (Executive Director, University of Kansas Center for Technology Commercialization)
Gail Cassell, PhD, DSc (hon) (Vice President, Scientific Affairs and Distinguished Research Scholar for Infectious Diseases, Eli Lilly and Company)
Vicki Seyfert-Margolis, Ph.D. (Advisor, Office of the Chief Scientist, Food and Drug Administration) (Invited)
Stephen P. Spielberg, M.D., Ph.D. (Director, Center for Personalized Medicine and Therapeutic Innovation, Children's Mercy Hospital)
Moderator: Lisa Richwine ( National Health Correspondent, Thomson-Reuters)

 

11:30 a.m. – 12:30 p.m. Pre-Lunch Program:
 A Conversation with Dr. Francis Collins (Director, National Institutes of Health) and Dr. Margaret Hamburg (Commissioner, Food and Drug Administration)
Moderator: Richard Gephardt, (Chairman, Council for American Medical Innovation)

 

 

 

 


12:30 p.m. – 1:00 p.m.
LUNCH

 

1:00 p.m. – 2:15 p.m.
Panel 3 - New Results
Louis DeGennaro, Ph.D. (Executive Vice President and Chief Mission Officer, The Leukemia & Lymphoma Society)
Scott Weir, Pharm.D., Ph.D. (Director, Institute for Advancing Medical Innovation, University of Kansas Cancer Center)
Tom Thornton (President and Chief Executive Officer, Kansas Bioscience Authority)
Michael Weingarten (Director, NCI SBIR and STTR Small Business Programs, National Cancer Institute)
Moderator: Lisa Richwine (National Health Correspondent, Thomson-Reuters)

 

2:15 p.m. – 3:30 p.m.
Panel 4 – New Paradigms in Cancer Research
Steven Averbuch, M.D. (Vice President, Oncology Transition Strategy & Development/Head, Pharmacodiagnostics Global Clinical Research, Bristol-Myers Squibb)
Frank Douglas, Ph.D., M.D. (President and CEO,The Austen BioInnovation Institute in Akron/Senior Fellow, Kauffman Foundation)
Roy Jensen, M.D. (Director, University of Kansas Cancer Center)
Ellen Sigal, Ph.D. (Chair and Founder, Friends of Cancer Research)
Moderator: Lisa Richwine (National Health Correspondent, Thomson-Reuters)

 

3:30 p.m. - 3:45 p.m. 
WRAP-UP

 

Questions/Contacts
For questions about meeting content, please contact Sara Weir at sara.weir@bakerd.com , (202) 312-7475 or Heather Chaney at hchaney@focr.org , (703)-302-1540.